Entering text into the input field will update the search result below

Adial Pharmaceuticals engages CRO to begin Phase 3 clinical trials of AD04

  • Adial Pharmaceuticals (NASDAQ:ADIL) announces Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD).
  • The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients, expected to begin in H1 2019.

Recommended For You

More Trending News

About ADIL Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ADIL--
Adial Pharmaceuticals, Inc.